Provided by Tiger Trade Technology Pte. Ltd.

Lantern Pharma Inc.

2.34
+0.05002.18%
Post-market: 2.380.0400+1.71%19:30 EDT
Volume:185.08K
Turnover:427.98K
Market Cap:29.86M
PE:-1.43
High:2.41
Open:2.32
Low:2.13
Close:2.29
52wk High:4.70
52wk Low:1.11
Shares:12.76M
Float Shares:10.14M
Volume Ratio:1.23
T/O Rate:1.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6362
EPS(LYR):-1.5709
ROE:-400.92%
ROA:-74.29%
PB:-9.28
PE(LYR):-1.49

Loading ...

Lantern Pharma files to sell 2.24M shares of common stock for holders

TIPRANKS
·
Jun 13

Lantern Pharma - Selling Stockholders May Sell up to 2.24 Mln Shares of Common Stock - SEC Filing

THOMSON REUTERS
·
Jun 13

Lantern Pharma - Lp-300 Plus Chemo Shows No Clinically Meaningful Toxicity Beyond Chemotherapy

THOMSON REUTERS
·
Jun 02

Lantern Pharma - Over 70% of L858r Patients Show Tumor Reduction; 77% Clinical Benefit Rate

THOMSON REUTERS
·
Jun 02

Lantern Pharma - Reports Lp-300 Pfs Benefit Deepens With Treatment Duration in L858r Lung Cancer

THOMSON REUTERS
·
Jun 02

Lantern Pharma - L858r Nsclc Patients Reached 8.9-Month Median Pfs With Lp-300; Durable Responses Beyond Two Years

THOMSON REUTERS
·
Jun 02

Lantern Pharma posts LP-300 Phase 2 HARMONIC trial presentation in EGFR L858R NSCLC

Reuters
·
Jun 02

Lantern Pharma Highlights Harmonic LP-300 Phase 2 Progress

TIPRANKS
·
Jun 02

Lantern Pharma shifts LP-300 Phase 2 HARMONIC trial to single-arm L858R focus

Reuters
·
May 19

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for Harmonic™ Phase 2 Trial of Lp-300 in Never-Smokers With Nsclc

THOMSON REUTERS
·
May 19

Lantern Pharma Inc - Harmonic Trial to Discontinue Control Arm of the Harmoni Trial and Migrate to Single-Arm Design

THOMSON REUTERS
·
May 19

Lantern Pharma Inc - Harmonic Trial to Increase Maximum Lp-300 Treatment Cycles to Eight

THOMSON REUTERS
·
May 19

Lantern Pharma Inc - FDA Raises No Objections to Key Proposed Harmonic Trial Amendments

THOMSON REUTERS
·
May 19

Lantern Pharma Inc - Harmonic Trial to Focus Enrollment on Egfr Exon 21 L858r Mutation Patients

THOMSON REUTERS
·
May 19

Lantern Pharma Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Lantern Pharma Q1 EPS $(0.30) Beats $(0.36) Estimate

Benzinga Earnings
·
May 16

Lantern Pharma Q1 FY26 net loss narrows 27% to USD 3.3 million

Reuters
·
May 16

Lantern Pharma Q1 EPS USD -0.3

THOMSON REUTERS
·
May 16

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

THOMSON REUTERS
·
May 16

Promising Penny Stocks To Consider In May 2026

Simply Wall St.
·
May 15